Instant Quality FISH. The name says it all.

Similar documents
Instant Quality FISH. The name says it all.

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

Three Hours Thirty Minutes

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Results you can trust

PRODUCT INFORMATION. New Reagents for Dako CoverStainer. Choose the H&E staining intensity you want.

The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link. Fully-Automated HbA 1c Testing

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link System. Fully-Automated HbA 1c Testing

artus EBV QS-RGQ Kit Performance Characteristics May 2012 Sample & Assay Technologies Analytical sensitivity plasma

HER2 IQFISH pharmdx. Code K th edition

TGX and TGX Stain-Free FastCast Acrylamide Kits

Prediction and Prevention of Type 1 Diabetes

PyroMark Q24 CpG MGMT Handbook

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance

Bio-Rad Laboratories. Hemoglobin Testing. VARIANT II Hemoglobin Testing System For HbA 1c

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Injection Techniques Questionnaire (ITQ) WorldWide Results Needle Gauge

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract

HER2 ISH (BRISH or FISH)

Breast Cancer Interpretation Guide

Comparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa

BioPlex 2200 Infectious Disease Panels

Type 1 Diabetes Australian Research Impact Analysis

Dr. dr. Primariadewi R, SpPA(K)

Allied Health: Sustainable Integrated Health Care for all Australians

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

T he HER2/neu type 1 tyrosine kinase growth factor

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

HER2/neu Evaluation of Breast Cancer in 2019

Tobacco control measures in the Dutch National Prevention Agreement and expected tobacco industry responses

GLP in the European Union Ecolabel detergents, GLP and accreditation

BEFLEX CUSTOMER SURVEY 2016

The next best thing to fruits and vegetables

The health economic landscape of cancer in Europe

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

Chemical compatibility of the Pall QPoint TM Docking Station - Tap Assembly with common surface disinfectants

WCPT COUNTRY PROFILE December 2017 SWEDEN

CANCER. Clinical Validation of Breast Cancer Predictive Markers

FOOD TESTING RAPID'L.Mono Chromogenic Media. Detect Listeria Species in 24 Hours

Immunohematology. IH-QC Modular System. Select. Combine. Control.

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

WCPT COUNTRY PROFILE December 2017 HUNGARY

POWERFUL PERSPECTIVES

European Community Pharmacy: a reference in Public Health

WCPT COUNTRY PROFILE December 2017 SERBIA

Cardiac Assessment Controls

Improving Food Process Control Using the

NobelProcera Implant Bar Overdenture complete range of fixed and removable solutions.

ZERENA THE NEW DYNAMICS OF HEARING CONTINUES... New options and possibilities for seamless and boundless hearing. Anytime, anywhere.

Comparison of Fluorescence and Chromogenic In Situ Hybridization for Detection of HER-2/neu Oncogene in Breast Cancer

Conducting Successful Oncology Clinical Trials in Asia Pacific: PharmaNet experience using Case Studies

IARC A UNIQUE AGENCY. Cancer research for cancer prevention

Journal of Breast Cancer

Population- based cancer survival estimates


PosterREPRINT INTRODUCTION. 2-D PAGE of Mouse Liver Samples. 2-D PAGE of E.coli Samples. Digestion / Cleanup. EXPERIMENTAL 1-D PAGE of BSA Samples

NATIONAL COST OF OBESITY SEMINAR. Dr. Bill Releford, D.P.M. Founder, Black Barbershop Health Outreach Program

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

MENTAL HEALTH DISORDERS: THE ECONOMIC CASE FOR ACTION Mark Pearson Head of Department, OECD Health Division

ETB Data. there was. compared

The Risk of Alcohol in Europe. Bridging the Gap June 2004

Global EHS Resource Center

SEAMLESS AND BOUNDLESS HEARING. ANYTIME, ANYWHERE. ZERENA

Third Party Controls for Your Dade Behring Systems

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

Engagement in language assessment / Regions of Europe

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Smokefree Policies in Europe: Are we there yet?

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

UW Medicine Neuropathology

Workflow. Connecting the Pieces For Total Patient Care

LEBANON. WCPT COUNTRY PROFILE December 2018

ab Luxol Fast Blue Stain (Myelin Stain)

Product Introduction

Urgent Medical Device Correction

European Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York

Protect Your Mass Spec

DENMARK. WCPT COUNTRY PROFILE December 2018

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

The OECD Health Care Quality Indicators Project

SS3 Series. Controlled Avalanche Power Diodes. Features: Mechanical Data: SMC/DO-214AB. Page 1 28/03/06 V1.0

Transform genomic data into real-life results

A New Era in SFC Column Technology

Navigate Complex Interventions at Every Turn

NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY

KEY WORDS: Breast carcinoma, c-erbb2, Fluorescent. Mod Pathol 2001;14(11):

Transcription:

PRODUCT INFORMATION HER2 IQFISH pharmdx Instant Quality FISH Instant Quality FISH. The name says it all. HER2 IQFISH pharmdx

IQ: Instant Quality every time. HER2 IQFISH pharmdx stains of a HER2 non-amplified (left) and a HER2 amplified (right) breast tumor. See acknowledgement. Dako s new IQFISH hybridization buffer is revolutionizing cancer diagnostics The cutting-edge IQFISH* hybridization buffer, introduced by Dako, reduces diagnostic test turnaround time from ~18 hours to less than 4 hours. Pathology labs can now perform DNA-based hybridization assays in much less time, with higher fluorescent signal intensity for better results compared to traditional FISH assays (1). This represents a major advance for pathologists and oncologists, and ultimately for patients. IQFISH hybridization buffer is free from formamide, making it a safer choice for your staff and the laboratory environment. HER2 IQFISH pharmdx is the first FDA-approved product that uses the revolutionary, non-toxic IQFISH hybridization buffer. Top-quality stains, combined with diagnostic certainty, speed and safety. That s real progress. * Patent pending

In summary, the 1-day HER2 IQFISH approach is a potent method for the determination of HER2 status offering some relevant advances further to the short incubation time, including enhanced tissue integrity and preserved fluorescent signal intensity when compared with the conventional HER2 FISH kit (2). Hegyi et al. Appl Immunohistochem Mol Morphol, 2013. Timeline for IQFISH procedure vs. traditional FISH Hours 0 2 4 6 8 10 12 14 16 18 IQFISH hybridization buffer with 1.5 hours hybridization 1.5 hours Traditional formamidebased buffer with overnight hybridization Overnight hybridization Deparaffinization Digestion Hybridization Mounting Heat pre-treatment Denaturation Stringent wash

IQFISH: Setting new standards for quality and speed. HER2 IQFISH pharmdx stain of a HER2 amplified breast tumor. See acknowledgement. In cancer diagnostics, providing the right diagnosis to the right patient on time is everything Top quality: Fast: Accurate: Non-toxic: Enhanced visualization of morphology and bright signals help pathologists identify cancer cells more easily. Crisp, clear signals make counting accurate, easy and fast. Hybridization takes only 1 to 2 hours with IQFISH hybridization buffer. Enhanced staining quality and a total turnaround time of less than 4 hours from dewax to counting. The ultimate combination of quality and speed. The robust assay delivers accurate results with high concordance to other FDA-approved FISH assays (3, 4). Protect the health and safety of your lab personnel by eliminating their exposure to formamide, which can cause harm to the fetus.

IQFISH provided excellent quality signals without any background staining. As a rule, DAPI stain and red and green signals were brighter with IQFISH than with FISH. The highly concordant data support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status. Use of this method could lead to reporting of HER2 status to the oncologist within a day (5). Franchet et al. Histopathol, 2013. HER2 IQFISH pharmdx Quantitatively determines HER2 gene amplification Identifies patients with breast or gastric cancer likely to benefit from Herceptin (trastuzumab) treatment Outstanding concordance to traditional FISH Concordance to HER2 FISH pharmdx of 98.6% for gastric cancer and 99.2% for breast cancer (3). Concordance to PathVysion of 100% for breast cancer (4). Brighter signals within 1 hour (1) Mean Fluorescence Intensity 60 50 40 30 20 10 0 Traditional FISH IQFISH 0 min 5 min 15 min 30 min 1 h 2 h 4 h 23 h Hybridization time Time-chase comparison of HER2 DNA FISH signal intensities using IQFISH hybridization buffer and formamide buffer on FFPE breast carcinoma tissue sections. The black bars represent the 95% confidence interval (n = 45 signals).

IQFISH: Save time, reduce costs and increase quality. HER2 IQFISH pharmdx stains of HER2 amplified (current page) and HER2 non-amplified breast tumors (opposite page). See acknowledgement. Superior performance of HER2 IQFISH pharmdx compared to a traditional HER2 FISH assay A study was conducted to compare two FDA-approved HER2 kits on almost 1500 patient samples tested over an eight-month period by ProPath Services. The results showed that HER2 IQFISH pharmdx : Saves time Less hands-on time and reduced risk of errors Shorter turnaround time Reduced scoring time Reduces costs Less repeat testing Reduced hands-on time Shorter interpretation time Increases quality Brighter signals Improved signal/background ratio More accurate analysis Download the white paper at www.dako.com/iqfish-study

In our opinion, the improved signal to background ratio generated by the HER2 IQFISH pharmdx assay allowed for a more accurate determination of copy numbers for both HER2 and the control probe. The HER2 IQFISH pharmdx assay also required significantly less time to score (6). Cohen and Alsobrook, 2014. HER2 IQFISH pharmdx kit includes: Dual-target probe mix (HER2/CEN-17) Pre-treatment solution Pepsin, ready-to-use Pepsin diluent Stringent wash buffer Wash buffer Fluorescence mounting medium, with DAPI Coverslip sealant Product Name Targets Indication Code HER2 IQFISH pharmdx HER2/CEN-17 Breast/Gastric K5731

Relentless in our commitment to fighting cancer. Together. Acknowledgement Special thanks to ProPath Services for supplying the stains presented in this brochure. The presented FISH images have not been edited or manipulated and are published in their original format as provided by ProPath Services, not in any way affiliated with Dako, an Agilent Technologies Company. References 1. Matthiesen SH and Hansen CM. Fast and non-toxic in situ hybridization without blocking of repetitive sequences. PloS One 2012;7: e40675. 2. Hegyi K, Lonborg C, Monus A, Mehes G. One-day FISH approach for the high-speed determination of HER2 gene copy status in breast carcinoma. Appl Immunohistochem Mol Morphol 2013;21:567-71. 3. Internal validation studies as referenced in the package insert for the HER2 IQFISH pharmdx kit. 4. Rüschoff J. HER2 IQFISH pharmdx in-situ hybridization results in 3½ hours - performance evaluation and clinical perspectives. Symposia at ECP 2012. www.dako.com/iqfish 5. Franchet C, Filleron T, Cayre A, Mounie E, Penault-Llorca F, Jacquemier J, et al. Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study. Histopathol 2014;64:274-83. 6. Cohen DS and Alsobrook S. ProPath Services, Dallas, TX. Improved quality and efficiency in manual preparation and analysis of formalin fixed paraffin embedded fluorescence in situ hybridization (FISH) specimens: A comparison of two FDA approved HER2 kits. White paper, 2014. www.dako.com/iqfish-study Corporate Headquarters Denmark +45 44 85 95 00 www.dako.com Represented in more than 100 countries Australia +61 2 9922 0700 Austria +43 1 408 43 34 0 Belgium +32 (0) 16 38 72 20 Brazil +55 11 50708300 Canada +1 905 335 3256 China +86 21 3612 7091 Denmark +45 44 85 97 56 Finland +358 9 348 73 950 France +33 1 64 53 61 44 Germany +49 40 69 69 470 Ireland +353 1 479 0568 Italy +39 02 58 078 1 Japan +81 3 5802 7211 Korea +82 2 402 6775 The Netherlands +31 20 42 11 100 Norway +47 23 14 05 40 Poland +48 58 661 1879 Spain +34 93 499 05 06 Sweden +46 8 556 20 600 Switzerland +41 41 760 11 66 United Kingdom +44 (0)1 353 66 99 11 United States of America +1 805 566 6655 29041 05MAY14 ROW Version